159 related articles for article (PubMed ID: 30605856)
1. Additional prognostic impact of the percentage of erythroid cells in the bone marrow of patients with myelodysplastic syndromes.
Neukirchen-Strapatsas J; Tuechler H; Porta MD; Fenaux P; Guerci A; Haas R; Rossi M; Sapena R; Sperr WR; Strupp C; Stamatoullas A; Valent P; Germing U; Bennett JM
Leuk Res; 2019 Feb; 77():8-13. PubMed ID: 30605856
[TBL] [Abstract][Full Text] [Related]
2. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R).
Calvo X; Arenillas L; Luño E; Senent L; Arnan M; Ramos F; Pedro C; Tormo M; Montoro J; Díez-Campelo M; Blanco ML; Arrizabalaga B; Xicoy B; Bonanad S; Jerez A; Nomdedeu M; Ferrer A; Sanz GF; Florensa L
Am J Hematol; 2017 Jul; 92(7):614-621. PubMed ID: 28370234
[TBL] [Abstract][Full Text] [Related]
3. Dysplastic erythroid precursors in the myelodysplastic syndromes and the acute myeloid leukemias: Is there biologic significance? (How should blasts be counted?).
Bennett JM; Tuechler H; Aul C; Strupp C; Germing U
Leuk Res; 2016 Aug; 47():63-9. PubMed ID: 27258735
[TBL] [Abstract][Full Text] [Related]
4. Prognostic evaluation of ALIP and CD34 immunostaining in IPSS-R subgroups of myelodysplastic syndromes.
Xiong B; Nie Y; Tang Z; Xue M; Zuo X
Pathology; 2017 Aug; 49(5):526-533. PubMed ID: 28669578
[TBL] [Abstract][Full Text] [Related]
5. High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes.
Alhan C; Westers TM; Cremers EM; Cali C; Witte BI; Ossenkoppele GJ; van de Loosdrecht AA
Br J Haematol; 2014 Oct; 167(1):100-9. PubMed ID: 24976502
[TBL] [Abstract][Full Text] [Related]
6. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.
Kao JM; McMillan A; Greenberg PL
Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988
[TBL] [Abstract][Full Text] [Related]
7. Elevated mature monocytes in bone marrow accompanied with a higher IPSS-R score predicts a poor prognosis in myelodysplastic syndromes.
Wu A; Gao P; Wu N; Shi C; Huang Z; Rong C; Sun Y; Sheng L; Ouyang G; Mu Q
BMC Cancer; 2021 May; 21(1):546. PubMed ID: 33985456
[TBL] [Abstract][Full Text] [Related]
8. Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes.
Lundberg LG; Hellström-Lindberg E; Kanter-Lewensohn L; Lerner R; Palmblad J
Leuk Res; 2006 Mar; 30(3):247-53. PubMed ID: 16099505
[TBL] [Abstract][Full Text] [Related]
9. Influence of Acute Myeloid Leukemia Progression on the Prognosis of 831 Patients With Myelodysplastic Syndromes From the Argentine Database.
Enrico A; Bestach Y; Flores MG; Arbelbide J; Serale C; Novoa V; Crisp R; Rivas MM; Larripa I; Belli C
Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):743-752.e5. PubMed ID: 28797621
[TBL] [Abstract][Full Text] [Related]
10. Can bone marrow cellularity help in predicting prognosis in myelodysplastic syndromes?
Greenbaum U; Joffe E; Filanovsky K; Oster HS; Kirgner I; Levi I; Raanani P; Avivi I; Manor E; Man-El G; Mittelman M
Eur J Haematol; 2018 Oct; 101(4):502-507. PubMed ID: 29956845
[TBL] [Abstract][Full Text] [Related]
11. Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index.
van Spronsen MF; Ossenkoppele GJ; Holman R; van de Loosdrecht AA
Eur J Cancer; 2014 Dec; 50(18):3198-205. PubMed ID: 25454415
[TBL] [Abstract][Full Text] [Related]
12. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
[TBL] [Abstract][Full Text] [Related]
13. Comparison of blast percentage calculated based on bone marrow all nucleated cells and non-erythroid cells in myelodysplastic syndromes with erythroid hyperplasia.
Mashima K; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Umino K; Minakata D; Nakano H; Yamasaki R; Morita K; Kawasaki Y; Sugimoto M; Ishihara Y; Ashizawa M; Yamamoto C; Fujiwara SI; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Ann Hematol; 2019 May; 98(5):1127-1133. PubMed ID: 30474718
[TBL] [Abstract][Full Text] [Related]
14. Revised international prognostic scoring system for myelodysplastic syndromes.
Greenberg PL; Tuechler H; Schanz J; Sanz G; Garcia-Manero G; Solé F; Bennett JM; Bowen D; Fenaux P; Dreyfus F; Kantarjian H; Kuendgen A; Levis A; Malcovati L; Cazzola M; Cermak J; Fonatsch C; Le Beau MM; Slovak ML; Krieger O; Luebbert M; Maciejewski J; Magalhaes SM; Miyazaki Y; Pfeilstöcker M; Sekeres M; Sperr WR; Stauder R; Tauro S; Valent P; Vallespi T; van de Loosdrecht AA; Germing U; Haase D
Blood; 2012 Sep; 120(12):2454-65. PubMed ID: 22740453
[TBL] [Abstract][Full Text] [Related]
15. Prognostic implications of bone marrow culturing in myelodysplastic syndrome: a retrospective analysis.
Raymakers R; Preijers F; Boezeman J; Rutten E; De Witte T
Leuk Lymphoma; 1994 Jun; 14(1-2):111-20. PubMed ID: 7920217
[TBL] [Abstract][Full Text] [Related]
16. Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution.
Bernasconi P; Klersy C; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Caresana M; Quarna J; Lazzarino M; Bernasconi C
Leukemia; 2005 Aug; 19(8):1424-31. PubMed ID: 15920496
[TBL] [Abstract][Full Text] [Related]
17. IPSS-R in 555 Taiwanese patients with primary MDS: Integration of monosomal karyotype can better risk-stratify the patients.
Yang YT; Hou HA; Liu CY; Lin CC; Chou WC; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Kuo YY; Huang SY; Ko BS; Chen CY; Hsu SC; Lin CT; Wu SJ; Tsay W; Chen YC; Tien HF
Am J Hematol; 2014 Sep; 89(9):E142-9. PubMed ID: 24845799
[TBL] [Abstract][Full Text] [Related]
18. Immunophenotyping in myelodysplastic syndromes can add prognostic information to well-established and new clinical scores.
Reis-Alves SC; Traina F; Harada G; Campos PM; Saad ST; Metze K; Lorand-Metze I
PLoS One; 2013; 8(12):e81048. PubMed ID: 24324660
[TBL] [Abstract][Full Text] [Related]
19. Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems.
Fu B; Jaso JM; Sargent RL; Goswami M; Verstovsek S; Medeiros LJ; Wang SA
Mod Pathol; 2014 May; 27(5):681-9. PubMed ID: 24186132
[TBL] [Abstract][Full Text] [Related]
20. Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy.
Radujkovic A; Dietrich S; Andrulis M; Benner A; Longerich T; Pellagatti A; Nanda K; Giese T; Germing U; Baldus S; Boultwood J; Ho AD; Dreger P; Luft T
Int J Cancer; 2016 Sep; 139(6):1402-13. PubMed ID: 27170453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
